Recent Updates
Recently added Catalysts

Samidorphan + olanzapine

Phase 2

Schizophrenia | Small molecule | Psychiatry |Alkermes plc|Last Updated: Oct 8, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment647
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02161718A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use DisorderPHASE2 COMPLETED 300May 1, 2014Feb 1, 2017Oct 8, 202171 United States, Bulgaria +1
NCT01903837A Study of ALKS 3831 in Adults With SchizophreniaPHASE2 COMPLETED 347Jun 1, 2013Mar 1, 2015Oct 6, 202161 United States, Bulgaria +1
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Independent Adjudication Committee (IAC) Adjudicated Event of Exacerbation of Disease (EEDS)
Up to 15 months

EEDS was defined as any of the following occurring during the double-blind period \& was related to worsening of disease symptoms, as confirmed by the Independent Adjudication Committee (IAC): 1. Hospitalization (includes psychiatric\& treatment of alcohol intoxication/withdrawal) 2. \>= 25% or \>= 15 point increase from randomization in PANSS total score 3. PANSS items score of P1, P2, P3, P6, P7 or G8 that meets 1 of the following: 3a. Score \>= 5 for subjects at a 2nd ad hoc visit with a score \<=3 at randomization 3b. Score \>= 6 for subjects at a 2nd ad hoc visit with a score =4 at randomization 4. Engagement in self injury, aggressive behavior, or suicidal/homicidal ideation 5. Initiation of rescue medication, including increase in olanzapine dosage initially prescribed at randomization 6. ER visit 7. Subject withdraws or PI discontinues subject for lack of efficacy, lost to follow-up, or withdrawal by subject 8. Arrest or incarceration related to subject's underlying disease

Absolute Change in Total Positive and Negative Syndrome Scale (PANSS) Score
Baseline (Day 8) to Day 92 (end of study Part A)

Change from baseline (Day 8) to Day 92 (end of study Part A). The PANSS is a 30-item scale measuring severity of schizophrenia symptoms. Symptom severity for each item is rated on a 7-point scale (1 = absent; 7 = extreme), and the total score is added together, with a minimum score of 30 and a maximum score of 210. A higher score indicates more severe symptoms, while a lower score indicates less severe symptoms.

Secondary Endpoints
Number of Events of Exacerbation of Disease (EEDS)
Up to 15 months
Number and Percentage of Subjects With at Least 1 Level Decrease in World Health Organization (WHO) Drinking Risk Level From Baseline to Week 24 of the Double-blind Treatment (Study Week 27)
24 weeks
Percent Change in Body Weight (Kilogram) From Baseline to Day 92
Baseline (Day 8) to Day 92 (end of study Part A)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Samidorphan + olanzapine (ALKS 3831)EXPERIMENTALActive study drug
Placebo + olanzapinePLACEBO_COMPARATOR -
Low DoseEXPERIMENTALOlanzapine + low dose samidorphan tablets taken once daily
Medium DoseEXPERIMENTALOlanzapine + medium dose samidorphan tablets taken once daily
High DoseEXPERIMENTALOlanzapine + high dose samidorphan tablets taken once daily
PlaceboPLACEBO_COMPARATOROlanzapine + placebo tablets taken once daily
Interventions
NameTypeDescription
Samidorphan + olanzapine (ALKS 3831)DRUGOral tablet, taken once daily
Placebo + olanzapineDRUGOral tablet, taken once daily
Samidorphan (Low Dose)DRUGTablets taken once daily
Samidorphan (Medium Dose)DRUGTablets taken once daily
Samidorphan (High Dose)DRUGTablets taken once daily
PlaceboDRUGTablets taken once daily
OlanzapineDRUGTablets taken once daily
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites71

Inclusion Criteria: * Has a BMI between 18.0 and 40.0 kg/m2, inclusive * Has a diagnosis of schizophrenia * Has a diagnosis of alcohol use disorder (AUD) * Has experienced an acute exacerbation of schizophrenia within the past 6 months * Additional criteria may apply Exclusion Criteria: * Is preg...

Countries:United StatesBulgariaPolandCzechia
Unlock Eligibility Criteria